title: Metabolic effects of short-term GLP-1 treatment in insulin resistant heart failure patients.
abstract: We studied the metabolic effects of 48-h GLP-1 treatment in insulin resistant heart failure patients.In a randomized placebo-controlled double-blinded cross-over study, 11 non-diabetic HF patients with IHD received 48-h GLP-1 and placebo-infusion. We applied OGTT, hyperinsulinemic clamp, indirect calorimetry, forearm, and tracer methods.7 insulin resistant HF (EF 28%±2) patients completed the protocol. GLP-1 decreased plasma glucose levels (p=0.048) and improved glucose tolerance. 4 patients had hypoglycemic events during GLP-1 vs. none during placebo. GLP-1 treatment tended to increase whole body protein turnover (p=0.08) but did not cause muscle wasting. No significant changes in circulating levels of insulin, glucagon, free fatty acids or insulin sensitivity were detected.GLP-1 treatment decreased glucose levels and increased glucose tolerance in insulin resistant HF patients with IHD. Hypoglycemia was common and may limit the use of GLP-1 in these patients. Insulin sensitivity, lipid-, and protein metabolism remained unchanged.Data were collected at the examinational laboratories of Department of Endocrinology and Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark.
authors.affiliation: Department of Endocrinology, Aarhus University Hospital, Aarhus Hospital, Aarhus, Denmark. roni.r.nielsen@gmail.com
authors.forename: R
authors.initials: R
authors.lastname: Nielsen
authors.forename: H
authors.initials: H
authors.lastname: Wiggers
authors.forename: M
authors.initials: M
authors.lastname: Halbirk
authors.forename: H
authors.initials: H
authors.lastname: Bøtker
authors.forename: J J
authors.initials: JJ
authors.lastname: Holst
authors.forename: O
authors.initials: O
authors.lastname: Schmitz
authors.forename: E
authors.initials: E
authors.lastname: Frandsen
authors.forename: S
authors.initials: S
authors.lastname: Nielsen
authors.forename: N
authors.initials: N
authors.lastname: Møller
authors.forename: H
authors.initials: H
authors.lastname: Nørrelund
mesh_terms: D001786:Blood Glucose / Q000378:metabolism*; D002153:Calorimetry, Indirect; D018592:Cross-Over Studies; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005230:Fatty Acids, Nonesterified / Q000097:blood; D005934:Glucagon / Q000097:blood; D052216:Glucagon-Like Peptide 1 / Q000008:administration & dosage*; D015309:Glucose Clamp Technique; D005951:Glucose Tolerance Test; D006333:Heart Failure / Q000188:drug therapy*; D006801:Humans; D007328:Insulin / Q000097:blood; D007333:Insulin Resistance / Q000502:physiology*; D008297:Male; D008875:Middle Aged
chemical_list: D001786:Blood Glucose; D005230:Fatty Acids, Nonesterified; D007328:Insulin; D052216:Glucagon-Like Peptide 1; D005934:Glucagon